Brought to you by 
Second round brings in $5mm for Tragara Pharmaceuticals
23 Feb 2010
Executive Summary
Tragara Pharmaceuticals (mainly oncology therapeutics; also has a personalized cancer diagnostic kit in development) raised $5mm from seven investors in its second financing round. Another $5mm is expected. While specific buyers were not disclosed, Tragara's Series A investors (which together put $40mm into the company in 2007) included Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners, and Mitsubishi.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Second round brings in $5mm for Tragara Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice